Mifegyne

Mifepristone, the active ingredient in Mifegyne, is an antiprogestogen (progesterone receptor antagonist) presented as a tablet for oral use. It blocks progesterone receptors, causing decidual breakdown and detachment of the embryo, and is used for the medical termination of intrauterine pregnancy up to 10 weeks in women.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Mifegyne (mifepristone) is used in the antiprogestogen pathway for early pregnancy termination.

Medical termination of intrauterine pregnancy up to 10 weeks: induces uterine lining breakdown and facilitates expulsion of the embryo when combined with misoprostol.

Mifegyne may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Abdominal pain or cramping - Vaginal bleeding or spotting - Nausea or vomiting - Diarrhea - Fatigue or weakness - Headache

Serious or Rare Side Effects: - Heavy bleeding requiring transfusion - Severe infection (sepsis) - Allergic reaction including anaphylaxis - Incomplete abortion needing surgical intervention - Uterine rupture (very rare) - Liver injury or abnormal liver function tests

Before prescribing Mifegyne, clinicians should observe several safety precautions. - Confirm gestational age: ensure pregnancy is ≤10 weeks by ultrasound or reliable dating. - Exclude ectopic pregnancy: perform appropriate evaluation to rule out ectopic location. - Assess contraindications: avoid in patients with chronic adrenal failure, long‑term corticosteroid therapy, or anticoagulant use. - Obtain informed consent: discuss expected outcomes, possible side effects, and need for follow‑up. - Arrange follow‑up care: schedule clinical assessment and ultrasound to confirm complete evacuation. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Mifegyne can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Systemic corticosteroids: may reduce effectiveness of mifepristone. - Anticoagulants (warfarin, DOACs): increase risk of severe bleeding. - Strong enzyme inducers (rifampin, carbamazepine): may lower plasma concentrations of mifepristone.

Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, fluconazole): may increase mifepristone levels. - Antiepileptic drugs (phenytoin, carbamazepine): may modestly reduce drug exposure. - St. John’s wort or other herbal enzyme inducers: potential reduction in drug levels.